Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Abeona Therapeutics Inc (NASDAQ: ABEO) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Abeona Therapeutics Inc (NASDAQ: ABEO)  concerning whether a series of statements by Abeona Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On December 12, 2016, a report released by Mako Research stated, in part, that Abeona's trial design for the Company's ABO-101 and ABO-102 gene therapy treatments was significantly flawed and scientifically unviable.  According to the report, Abeona's Executive Chairman and Principal Executive Officer,  Steven Rouhandeh, was the managing director at D. Blech & Co, a brokerage firm that was the subject of SEC investigations during the 1990s as well as a securities class action suit that ended in a $15 million investor settlement due to claims that the firm changed the price of some biotech stocks through transactions that falsely inflated the market price of the stocks to maintain the firm’s interest in these stocks.

On this news, NASDAQ: ABEO fell $0.70, or 13.59%, to close at $4.45 on December 12, 2016.

Based in Dallas, Texas, and founded in 1989 Abeona Therapeutics Inc is engaged in developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases.

If you purchased shares of Abeona Therapeutics Inc (NASDAQ: ABEO) on or before December 12, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185